Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$197.44 USD

197.44
4,182,372

-0.11 (-0.06%)

Updated Aug 26, 2024 04:00 PM ET

Pre-Market: $197.33 -0.11 (-0.06%) 8:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Top Ranked Income Stocks to Buy for October 17th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 17th.

Is AbbVie (ABBV) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here is Why Growth Investors Should Buy AbbVie (ABBV) Now

AbbVie (ABBV) possesses solid growth attributes, which could help it handily outperform the market.

Top Ranked Momentum Stocks to Buy for October 16th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 16th.

Reata Successfully Completes Neuromuscular Disorder Study

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

Kinjel Shah headshot

Allergan (AGN) Shareholders Approve Acquisition by AbbVie

Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View

J&J (JNJ) comes up with encouraging third-quarter 2019 results.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $73.76, moving +0.18% from the previous trading session.

This is Why AbbVie (ABBV) is a Great Dividend Stock

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.

Top Ranked Income Stocks to Buy for October 10th

Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 10th.

J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case

Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.

Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan

Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.

AbbVie (ABBV) Stock Moves -0.44%: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $74.33, moving -0.44% from the previous trading session.

Urmimala Biswas headshot

5 Excellent GARP Picks Based on Discounted PEG

While P/E gives an idea of stocks trading at a discount, PEG helps to find stocks with solid future potential.

The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie

The Zacks Analyst Blog Highlights: Cintas, Air Products, Walmart, Target and AbbVie

John Blank headshot

Chaos Politics to Slow Growth, or Vice-Versa? Zacks October Market Strategy

Do you start off with slow growth in a given Country, and then voters get angry about it? Or do angry voters, with nothing to complain about, get angry anyways, and slow down their economy's growth?

John Blank headshot

Chaos Politics to Slow Growth, or Vice-Versa? Zacks October Market Strategy

Do you start off with slow growth in a given Country, and then voters get angry about it? Or do angry voters, with nothing to complain about, get angry anyways, and slow down their economy's growth?

Novartis Reports Additional Data on Spondylitis Drug Cosentyx

Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.

Tirthankar Chakraborty headshot

5 Dividend Aristocrats to Buy as October Sees a Shaky Start

With things looking dicey for the stock market this October, it's prudent to invest in dividend aristocrats for their risk-adjusted returns.

Vertex Enters Into Collaboration With Privately-Held Ribometrix

Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.

The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square

The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square

Top Ranked Income Stocks to Buy for October 2nd

Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 2nd.

Mark Vickery headshot

Top Stock Reports for AbbVie, Starbucks & Phillips 66

Today's Research Daily features new research reports on 12 major stocks, including AbbVie (ABBV), Starbucks (SBUX) and Phillips 66 (PSX).

AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

AbbVie (ABBV) closed at $75.73 in the latest trading session, marking a +1.18% move from the prior day.